Pembrolizumab Immune-Related Adverse Event Severity Score

Grade pembrolizumab and other PD-1/PD-L1 inhibitor immune-related adverse events by organ system using CTCAE v5, with NCCN/SITC-aligned management (hold, high-dose steroids, infliximab, hospitalization).

Weight
Height
Clinical Guidance

BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).

BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.
Advertisement

How It Works

Grade pembrolizumab and other PD-1/PD-L1 inhibitor immune-related adverse events by organ system using CTCAE v5, with NCCN/SITC-aligned management (hold, high-dose steroids, infliximab, hospitalization)

Each component has a specific meaning:

  • CTCAE v5 — The ctcae v5 recorded for the scenario being assessed.

Note: Interpret the pembrolizumab irae score result against the thresholds and context described above.

How to Use

Enter the CTCAE v5 for the scenario you are assessing. Grade pembrolizumab and other PD-1/PD-L1 inhibitor immune-related adverse events by organ system using CTCAE v5, with NCCN/SITC-aligned management (hold, high-dose steroids, infliximab, hospitalization). Use the pembrolizumab irae score result to inform your calculation.

Related Calculators

Nivolumab Response Probability

Medical Long-tail

Frequently Asked Questions